Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
440 SEK | 0.00% | +252.00% | +312.01% |
14/06 | Enveda Therapeutics, Inc. announced that it has received $55 million in funding from a group of investors | CI |
05/06 | Kinnevik AB Approves Extra Distribution | CI |
Sales 2024 * | 4.31B 410M 34.23B | Sales 2025 * | 5.3B 504M 42.12B | Capitalization | 27.18B 2.59B 216B |
---|---|---|---|---|---|
Net income 2024 * | 4.06B 386M 32.27B | Net income 2025 * | 5.03B 479M 39.98B | EV / Sales 2024 * | 7.38 x |
Net Debt 2024 * | 4.6B 438M 36.57B | Net Debt 2025 * | 4.83B 460M 38.4B | EV / Sales 2025 * | 6.04 x |
P/E ratio 2024 * |
6.64
x | P/E ratio 2025 * |
5.36
x | Employees | 46 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.04% |
Latest transcript on Kinnevik AB
1 week | +252.00% | ||
Current month | +258.89% | ||
1 month | +247.55% | ||
3 months | +297.83% | ||
6 months | +300.00% | ||
Current year | +312.01% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 48 | 01/18/01 | |
Samuel Sjöström
DFI | Director of Finance/CFO | 37 | 01/13/01 |
Chief Investment Officer | 53 | 01/21/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Anderson
CHM | Chairman | 65 | 29/21/29 |
Director/Board Member | 65 | 01/18/01 | |
Olof Harald Mix
BRD | Director/Board Member | 64 | 29/21/29 |
Date | Price | Change | Volume |
---|---|---|---|
14/24/14 | 98.6 | -2.38% | 1,080 |
13/24/13 | 101 | -3.63% | 1,776 |
12/24/12 | 104.8 | +4.80% | 2,056 |
11/24/11 | 100 | -6.33% | 288 |
Delayed Quote London S.E., June 06, 2024 at 08:55 pm IST
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+22.07% | 82.37B | |
+12.85% | 17.96B | |
+53.39% | 16.87B | |
+7.94% | 14.53B | |
-5.78% | 12.16B | |
+8.19% | 11.06B | |
0.00% | 11B | |
+23.69% | 9.73B | |
-6.28% | 9.22B |
- Stock Market
- Equities
- KINV B Stock
- 0RGZ Stock